Dechra Pharmaceuticals Plc Stock Book Value Per Share
| DPHAYDelisted Stock | USD 93.78 0.00 0.00% |
Dechra Pharmaceuticals PLC fundamentals help investors to digest information that contributes to Dechra Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Dechra Pink Sheet. The fundamental analysis module provides a way to measure Dechra Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Dechra Pharmaceuticals pink sheet.
Dechra |
Dechra Pharmaceuticals PLC Company Book Value Per Share Analysis
Dechra Pharmaceuticals' Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Dechra Pharmaceuticals Book Value Per Share | 12.30 X |
Most of Dechra Pharmaceuticals' fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Dechra Pharmaceuticals PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
CompetitionIn accordance with the recently published financial statements, the book value per share of Dechra Pharmaceuticals PLC is about 12.304 times. This is 823.76% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The book value per share for all United States stocks is 99.36% higher than that of the company.
Dechra Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Dechra Pharmaceuticals' direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Dechra Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Dechra Pharmaceuticals by comparing valuation metrics of similar companies.Dechra Pharmaceuticals is currently under evaluation in book value per share category among its peers.
Dechra Fundamentals
| Return On Equity | 0.0896 | |||
| Return On Asset | 0.0478 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.14 % | |||
| Current Valuation | 4.04 B | |||
| Shares Outstanding | 56.92 M | |||
| Shares Owned By Institutions | 0.09 % | |||
| Price To Book | 4.99 X | |||
| Price To Sales | 5.65 X | |||
| Revenue | 681.8 M | |||
| Gross Profit | 384.8 M | |||
| EBITDA | 178.9 M | |||
| Net Income | 58.2 M | |||
| Cash And Equivalents | 123.7 M | |||
| Cash Per Share | 2.29 X | |||
| Total Debt | 313.7 M | |||
| Debt To Equity | 0.49 % | |||
| Current Ratio | 2.91 X | |||
| Book Value Per Share | 12.30 X | |||
| Cash Flow From Operations | 122.9 M | |||
| Earnings Per Share | 1.29 X | |||
| Number Of Employees | 2 K | |||
| Beta | 0.68 | |||
| Market Capitalization | 4.3 B | |||
| Total Asset | 1.29 B | |||
| Z Score | 7.8 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 1.29 B | |||
| Last Dividend Paid | 0.45 |
About Dechra Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Dechra Pharmaceuticals PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dechra Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dechra Pharmaceuticals PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Consideration for investing in Dechra Pink Sheet
If you are still planning to invest in Dechra Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Dechra Pharmaceuticals' history and understand the potential risks before investing.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |